Use of botulinum toxin for movement disorders

Article Details

Carlos Henrique Ferreira Camargo MD, MSc, PhD, Hélio Afonso Ghizoni Teive MD, MSc, PhD

Article Type


Related Articles

Article Page


The term movement disorders encompasses all disorders hypokinetic and hyperkinetic, which were previously known as extrapyramidal syndromes. With the definition of movement disorders and their diagnostic criteria and classifications, new studies for therapeutics could be performed. New drugs were launched, functional neurosurgery was developed, and the introduction of botulinum toxin (BoNT) for hyperkinesias was introduced. BoNT is an important therapy for dystonia, tics, myoclonus, and tremors. The aim of this review is to present the new and well-established uses of BoNT for movement disorders.

Keywords: botulinum toxin, dystonia, hyperkinesias, movement disorders, Parkinson’s disease, spasticity.

Citation: Camargo CHF, Teive HAG. Use of botulinum toxin for movement disorders. Drugs in Context 2019; 8: 212586. DOI: 10.7573/dic.212586

Contributions: We confirm that the manuscript has been read and approved by both named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by both of us. Both named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2019 Camargo CHF, Teive HAG. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Camargo CHF, Teive HAG. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL:

Correspondence: Carlos Henrique Ferreira Camargo, Programa de Pós Graduaçao em Medicina Interna – Hospital de Clínicas – UFPR; Rua General Carneiro,181 – Alto da Glória Curitiba-PR, Brazil.

Provenance: invited; externally peer reviewed.

Submitted: 19 March 2019; Peer review comments to author: 17 May 2019; Revised manuscript received: 23 May 2019; Accepted: 23 May 2019; Publication date: 18 June 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief

For all permissions, rights and reprints, contact David Hughes

Download free full text PDF